HMGCR and type 2 diabetes mellitus: Patients with NAFLD (with or without T2DM) should have cardiovascular risk assessment using QRISK3 assessment tool, and those with 10% or greater 10-year risk of developing CVD should be offered HMG-CoA reductase inhibitor (“statin”) therapy for primary prevention 89, 91.